Agenus AGEN stock price, is it time to sell or rebuy? Exclusive analysis!


Agenus AGEN stock price and chart looks great, is it time to sell...

Stay Ahead of the
Stock Market Game!
Subscribe to Small Cap
Exclusive for more


Kingstown Capital Partners is Buying Novelion Therap...
Farallon Capital is Buying Radius Health Inc. (NASDA...
Liquidia LQDA Stock Price, are you kidding me? URGEN...

Agenus AGEN stock price and chart looks great, is it time to sell or rebuy? Famed stock picker, Alexander Goldman has his analysis, take a look below.

Before we do, remember to stop what you are doing and 👇 Sign up for our newsletter to get the latest breakout stocks and trending stocks!

[thrive_leads id=’14274′]

Before we get started, I wanted to introduce myself to you. Hi 🙋‍♂️ I’m Alexander Goldman and I have been successfully trading breakout stocks and trending stocks for two decades now.

I’m now helping traders find breakout stocks. My claim to fame is the expert at finding trending stocks.

What do I mean by big winners?

Stocks that move more than 100% in a month! AGEN Stock Price could?

Does that always happen, NO! But, I’m very good! Take a look at this article I wrote, where I called 5 stocks, 3 losers and 2 winners and they all did what I thought!

The article is HERE where I shine a spotlight on trending stocks and breakout stocks!

If you want stocks delivered to your inbox, no hassle, no research with this massive community of traders, sign up below. Now, let’s go over some of the basic information on this stock before we get in the technical analysis.

Agenus Company Information

Company Name: Agenus Inc.

Ticker: AGEN

Exchange: NASDAQ


Agenus Company Summary:

Agenus discovers, manufactures and develops immuno-oncology products. The company’s I-O portfolio is comprised of checkpoint antibodies, cell therapies, vaccines, and adjuvants, representing a combination of synergistic agents to deliver curative patient outcomes

AGEN stock price is due to News?

Jun 29, 2022

Announced expanded data from the Phase 1b study of botensilimab (Fc-enhanced anti-CTLA-4) and balstilimab (anti-PD-1) in patients with microsatellite stable colorectal cancer (MSS CRC). The data demonstrate that the combination offers strong durability and superior efficacy than what has been reported in separate trials for standard of care and other investigational therapies in 2L+ MSS CRC.

AGEN 5 Day Chart

AGEN Stock Price Technical Analysis:

The chart looks good only if it can beat it’s last resistance point. I like the stock it is bullish and the 5 day chart looks amazing.

Once again my name is Alex and I’m so glad you took the time to read this far. I would love to have you be apart of our growing family of traders.

I always like giving tid bits of knowledge that I have learned from my mentors, so here goes. As a reminder to all of the traders out there to leave your emotions at the door and never, ever, try to catch a falling safe. Simply let it crash to the ground and then, walk over and pick up the money. That is a reference to bounce plays LOL.

I strive to find breakout stock alerts and deliver them before the market finds out. I’m the original OG trend setter of trending stocks! If you want stocks delivered to your inbox, no hassle, no research with this massive community of traders, sign up below.

I sure hope you enjoyed this article, if you would like to receive more exclusive content from me sign up for our newsletter below 👇

[thrive_leads id=’14274′]

Stay in the lopp :

OWUV Stock Price is consolidated, is it ready...

One World Universe OWUV stock price is up 4% in the last 5 days, but the real question is, is this

HPIL Holding (HPIL) Stock Continues to Hit Ne...

There were many stocks that made considerable gains last week and one of those was the Cybernetics Technologies Ltd or HPIL Holding (OTCMKTS:HPIL)

Capital World Investors is Buying Chubb Ltd. ...
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Chubb Ltd. (NYSE:CB) reported that Capital World Investors has picked

related post

Skip to content